Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mohamed Altai

Showing results (41-50 of 62) with videos related to

Pageof 7
Sort By:
Amino Acids|May 6, 2018
Influence of composition of cysteine-containing peptide-based chelators on biodistribution of <sup>99m</sup>Tc-labeled anti-EGFR affibody moleculesMaryam Oroujeni, Ken G Andersson, Xenia Steinhardt, et al.
Bioconjugate Chemistry|December 19, 2013
Incorporation of a triglutamyl spacer improves the biodistribution of synthetic affibody molecules radiofluorinated at the N-terminus via oxime formation with (18)F-4-fluorobenzaldehydeDaniel Rosik, Alf Thibblin, Gunnar Antoni, et al.
Pharmaceutics|June 18, 2020
Evaluating the Therapeutic Efficacy of Mono- and Bivalent Affibody-Based Fusion Proteins Targeting HER3 in a Pancreatic Cancer Xenograft ModelCharles Dahlsson Leitao, Sara S Rinne, Mohamed Altai, et al.
Pharmaceutics|April 30, 2020
HER2-Specific Pseudomonas Exotoxin A PE25 Based Fusions: Influence of Targeting Domain on Target Binding, Toxicity, and In Vivo BiodistributionHaozhong Ding, Mohamed Altai, Wen Yin, et al.
Pharmaceutics|November 27, 2021
The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy EfficacyWen Yin, Tianqi Xu, Mohamed Altai, et al.
Biomaterials|October 29, 2020
Radionuclide therapy using ABD-fused ADAPT scaffold protein: Proof of PrincipleJavad Garousi, Emma von Witting, Jesper Borin, et al.
European Journal of Medicinal Chemistry|October 6, 2014
Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with (188)ReMohamed Altai, Hadis Honarvar, Helena Wållberg, et al.
Biomolecules|February 13, 2021
<sup>177</sup>Lu-PSMA-617 Therapy in Mice, with or without the Antioxidant α<sub>1</sub>-Microglobulin (A1M), Including Kidney Damage Assessment Using <sup>99m</sup>Tc-MAG3 ImagingAmanda Kristiansson, Anders Örbom, Jonas Ahlstedt, et al.
Molecules (Basel, Switzerland)|July 19, 2014
The effect of mini-PEG-based spacer length on binding and pharmacokinetic properties of a 68Ga-labeled NOTA-conjugated antagonistic analog of bombesinZohreh Varasteh, Ulrika Rosenström, Irina Velikyan, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 14, 2014
Imaging of HER3-expressing xenografts in mice using a (99m)Tc(CO) 3-HEHEHE-Z HER3:08699 affibody moleculeAnna Orlova, Magdalena Malm, Maria Rosestedt, et al.
Pageof 7

Showing results (41-50 of 62) with videos related to

Sort By:
Pageof 7
Amino Acids|May 6, 2018
Influence of composition of cysteine-containing peptide-based chelators on biodistribution of <sup>99m</sup>Tc-labeled anti-EGFR affibody moleculesMaryam Oroujeni, Ken G Andersson, Xenia Steinhardt, et al.
Bioconjugate Chemistry|December 19, 2013
Incorporation of a triglutamyl spacer improves the biodistribution of synthetic affibody molecules radiofluorinated at the N-terminus via oxime formation with (18)F-4-fluorobenzaldehydeDaniel Rosik, Alf Thibblin, Gunnar Antoni, et al.
Pharmaceutics|June 18, 2020
Evaluating the Therapeutic Efficacy of Mono- and Bivalent Affibody-Based Fusion Proteins Targeting HER3 in a Pancreatic Cancer Xenograft ModelCharles Dahlsson Leitao, Sara S Rinne, Mohamed Altai, et al.
Pharmaceutics|April 30, 2020
HER2-Specific Pseudomonas Exotoxin A PE25 Based Fusions: Influence of Targeting Domain on Target Binding, Toxicity, and In Vivo BiodistributionHaozhong Ding, Mohamed Altai, Wen Yin, et al.
Pharmaceutics|November 27, 2021
The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy EfficacyWen Yin, Tianqi Xu, Mohamed Altai, et al.
Biomaterials|October 29, 2020
Radionuclide therapy using ABD-fused ADAPT scaffold protein: Proof of PrincipleJavad Garousi, Emma von Witting, Jesper Borin, et al.
European Journal of Medicinal Chemistry|October 6, 2014
Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with (188)ReMohamed Altai, Hadis Honarvar, Helena Wållberg, et al.
Biomolecules|February 13, 2021
<sup>177</sup>Lu-PSMA-617 Therapy in Mice, with or without the Antioxidant α<sub>1</sub>-Microglobulin (A1M), Including Kidney Damage Assessment Using <sup>99m</sup>Tc-MAG3 ImagingAmanda Kristiansson, Anders Örbom, Jonas Ahlstedt, et al.
Molecules (Basel, Switzerland)|July 19, 2014
The effect of mini-PEG-based spacer length on binding and pharmacokinetic properties of a 68Ga-labeled NOTA-conjugated antagonistic analog of bombesinZohreh Varasteh, Ulrika Rosenström, Irina Velikyan, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 14, 2014
Imaging of HER3-expressing xenografts in mice using a (99m)Tc(CO) 3-HEHEHE-Z HER3:08699 affibody moleculeAnna Orlova, Magdalena Malm, Maria Rosestedt, et al.
Pageof 7